Warfarin-induced skin necrosis

Seema Inayatullah1, Gautam Phadke, Leonid Vilenski

  • 1MeritCare Health System, Department of Internal Medicine, University of North Dakota School of Medicine, Fargo, ND, USA.

Southern Medical Journal
|December 10, 2009
PubMed

Insights

Guidelines are lacking for managing warfarin-induced skin necrosis, including heparin use and warfarin continuation. This case report highlights challenges in vitamin K antagonist therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Dermatology

Background:

  • Warfarin therapy is crucial for preventing thromboembolic events but carries risks, including skin necrosis.
  • Warfarin-induced skin necrosis (WISN) is a rare but severe complication requiring careful management.
  • Current clinical guidelines for managing WISN are limited, particularly concerning anticoagulation strategies.

Observation:

  • This case report details a patient experiencing warfarin-induced skin necrosis.
  • The report focuses on the complexities of intravenous heparin administration and subsequent warfarin use.
  • Challenges in patient selection and treatment duration for heparin were encountered.

Findings:

  • A significant gap exists in established protocols for heparin selection and duration in WISN cases.
  • Managing vitamin K antagonist (VKA) therapy presents considerable clinical challenges.
  • The report underscores the need for clearer guidelines in preventing and treating WISN.

Implications:

  • This case highlights the critical need for evidence-based guidelines in managing warfarin-induced skin necrosis.
  • Improved understanding and protocols can enhance patient outcomes and reduce complications associated with VKA therapy.
  • Further research is warranted to address the therapeutic uncertainties in WISN management.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...